Ovarian Cancer News and Research

RSS

Commonly known as the "silent killer," ovarian cancer leads to approximately 15,000 deaths each year in the United States, according to the American Cancer Society. Approximately 20,000 new cases are diagnosed each year, with the majority in patients diagnosed with late stage disease where the cancer has spread beyond the ovary. The prognosis is poor in these patients, leading to the high mortality from this disease. A diagnostic test is needed that can provide adequate predictive value to stratify patients with a pelvic mass into high risk of invasive ovarian cancer versus those with low risk, as well as a screening test for the diagnosis of early-stage ovarian cancer, which is essential for improving overall survival in patients. Ovarian cancer has up to a 90% cure rate following surgery and/or chemotherapy if detected in stage 1.

Robust new method accurately identifies eight antidepressants

In recent years, a mass spectrometry process that can detect the amounts of drugs in a biological sample, such as blood, has become a powerful diagnostic tool for helping medical professionals identify and monitor levels of therapeutic drugs in patients, which can cause unwanted or dangerous side effects.

14 Feb 2023

Treating ovarian cancer with immunotherapy involving CAR T cells

Recent research revealed that CAR T-cell therapy, a particular type of cancer treatment in which the immune system’s T cells are directed to kill tumor cells, is successful in treating ovarian cancer in mice.

7 Feb 2023

CAR T-cell therapy effective in mice with ovarian cancer

CAR T-cell therapy, a certain kind of cancer treatment in which the immune system's T cells are programmed to attack tumor cells, is effective in mice with ovarian cancer, according to a study published in The Journal for ImmunoTherapy of Cancer.

6 Feb 2023

Novel adoptive T cell receptor therapy shows promising results for patients with solid tumors

Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4), an adoptive T cell receptor (TCR) therapy targeting the MAGE-A4 cancer antigen, achieved clinically significant results for patients with multiple solid tumor types in a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

30 Jan 2023

Point-of-care program boosts genetic testing for prostate cancer

Certain prostate cancer patients have genetic mutations that could affect how they are treated. According to a study published in Urology Practice®, an Official Journal of the American Urological Association (AUA), a comprehensive, on-site genetic testing program developed by urologists could help close the gap for this underutilized resource.

16 Dec 2022

Importance of localizing BRCA gene mutations for ovarian cancer treatment

Mutations in the BRCA1 and BRCA2 genes, which are inherited by 1 in 400 and 1 in 800 persons, respectively, elevate the risk of various malignancies such as ovarian, breast, pancreatic, and prostate cancer considerably.

30 Nov 2022

WEHI receives $2.5 million fund to develop personalized cancer treatments

With a $2.5 million fund received from the Medical Research Future Fund (MRFF), a new genomics project led by WEHI will develop precision medicine and customized cancer therapy for Australians.

From Walter and Eliza Hall Institute of Medical Research (WEHI) 27 Sep 2022

New type of chip could lead to earlier and more targeted treatment for cancer

Cancer spreads via circulating tumor cells (CTCs) that travel through the blood to other organs, and they are nearly impossible to track.

17 Aug 2022

ZDHHC18-mediated MDH2 palmitoylation upholds mitochondrial respiration and boosts ovarian cancer malignancy

To drive anabolic processes, epithelial ovarian cancer (EOC) is heavily reliant on the tricarboxylic acid (TCA) cycle and oxidative phosphorylation.

13 Jun 2022

Researchers analyze the involvement of immune cells in lung cancer survival

Lung cancer affects approximately 48,500 persons in the United Kingdom every year. New treatments are urgently needed because only around 20% of patients live 5 years after diagnosis, and it is the leading cause of cancer death.

1 Jun 2022

Study shows new potential target for CAR T cells to inhibit solid tumors

CAR T therapy, or chimeric antigen receptor T-cell therapy, has revolutionized the treatment of some blood cancers, allowing patients with relapsed or refractory disease to live longer and better lives.

10 May 2022

Scientists discover an effective drug development candidate from rare actinomycetes

Researchers are rushing to review a group of bacteria known as actinomycetes, which are one of the most successful sources of treatment.

19 Apr 2022

A new rule book for the design of therapeutic cells with improved specificity and safety

Therapies based on engineered immune cells have recently emerged as a promising approach in the treatment of cancer.

18 Apr 2022

Study reveals key characteristics of immune cells in ovarian cancer

Ovarian cancer is a difficult to diagnose malignancy that is often caught at a more advanced stage. Treatments for this cancer have changed little over the past few decades, with surgery and chemotherapy being the most common therapeutic approaches.

15 Apr 2022

Specialist assay kits and microplates for cancer research

Porvair Sciences will exhibit its latest assay kits and microplates for cancer and life science research at the American Association for Cancer Research (AACR) meeting in New Orleans, USA from the 8th – 13th April 2022.

From Porvair Sciences Limited 7 Apr 2022

Study identifies a new cancer cell state related to poor treatment response in ovarian cancer patients

The prognosis for ovarian cancer patients is grim: less than half of high-grade serous ovarian cancer (HGSC) patients survive past five years from diagnosis. Initially, the tumors typically respond well to chemotherapy but become resistant after repeated treatments, enabling the cancer to regrow.

24 Feb 2022

Study identifies genes that protect ovarian cancer from antitumor immunity

Immunotherapies are exhibiting better clinical benefit in the treatment of numerous cancers, particularly when used along with chemotherapy.

2 Dec 2021

Constitutive BAK/MCL1 complexes could predict sensitivity of chemotherapy drugs, research shows

A research team led by Prof. DAI Haiming from the Hefei Institutes of Physical Science of the Chinese Academy of Sciences recently announced the constitutive BAK/MCL1 complexes could predict chemotherapy drugs sensitivity of ovarian cancer. The result has been published on Cell death & disease.

16 Sep 2021

Researchers reveal how cancerous tissues develop resistance to platinum-based cytotoxic drugs

Cancer cells sometimes develop resistance to the cytotoxic drugs used in chemotherapy. Figuring out why the treatment isn't working and why it may even defeat its own purpose is therefore important to understand.

9 Aug 2021

Study analyzes individuals’ stance on secondary genomic findings

Recent research disclosed that around half of the people who refused to receive secondary genomic findings switched opinions after their healthcare provider presented them with further information.

From National Human Genome Research Institute (NHGRI) 2 Aug 2021